🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Comprehensive Genomic Profiling leads to better patient outcomes in new joint study from Providence Chiles Research Institute Illumina & Microsoft. Congrats Alexa Brian Piening Rom Leidner carlobifulco and team. #FinishCancer Journal of Clinical Oncology   blog.providence.org/national-news/…

I am deeply honored to succeed Dr. Urba & I am committed to building upon his legacy of transformational  immuno-oncology research & a world-class cancer center dedicated to translating the next generation of immunotherapies from lab bench to the bedside. Chiles Research Institute

👏Congrats to Thomas Duhen PhD, Olivier Fesneau, PhD and our #FINISHCANCER team for their work just published in Nature Cancer 'IL-12 drives the expression of the inhibitory receptor NKG2A on human tumor-reactive CD8 T cells' rdcu.be/d0A7V

Exchange of information is critical to furthering our mission Chiles Research Institute of developing better cancer therapies, which is why we host visiting professors. Thank you Stefani Spranger Massachusetts Institute of Technology (MIT) for your time & sharing your work on how dendritic cells shape immunity. Providence

IL-12 drives the expression of NKG2A on human tumor-reactive CD8 T cells - Thomas Duhen oncodaily.com/url/190679 Bernard A Fox Nature Communications Chiles Research Institute #Cancer #ImmuneOnc #IO #ImmunoOncology #MedEd #MedX #MedNews #Health #Medicine #OncoDaily #Oncology

Thanksgiving is more than a holiday, it's an opportunity to appreciate our families, friends, and communities. We thank our Providence Oregon caregivers for their dedication and compassion. To our patients, thank you for entrusting us with your care. Wishing you a Happy Thanksgiving.

Fesneau et al. showed that in HNSCC and CRC tumors, expression of the inhibitor NKG2A, a receptor for HLA-E that is associated with poor prognosis for many solid cancers, was upregulated upon differentiation of [...] bit.ly/3D2hZCb  Chiles Research Institute

Be sure to tune in to KATU News Afternoon Live today (12/9) at 2:00 p.m. as our R. Bryan Bell, MD, DDS, FACS, FRCS(Ed) discusses his transition to executive medical director of Providence Cancer Institute and director of the Chiles Research Institute. katu.com/afternoon-live #FINISHCANCER

As we prepare to start a new year, we reflect on our commitment to advancing cancer care and research for the benefit of our patients and communities. Looking back, there’s much to celebrate and much more to look forward to. Read about our year: blog.providence.org/cancer/a-year-….

Wishing you a holiday season of peace, love, and meaningful moments with family and friends. From all of us at Providence Cancer Institute and Earle A. Chiles Research Institute, happy holidays and best wishes for the new year.

Earle A. Chiles Research Institute’s tripling of response rates for patients with head and neck cancer – Bernard A Fox (Chiles Research Institute/UbiVac/OHSU School of Medicine) oncodaily.com/insight/211553 #Health #Medicine #Cancer #OncoDaily #Oncology #HeadAndNeckCancer

2025 marks a big change for us as R. Bryan Bell, MD, DDS, FACS, FRCS(Ed) begins his new leadership roles at PCI and Chiles Research Institute. He stopped by KATU News to share his vision for the future of cancer care. Watch youtube.com/watch?v=naluIR…. #FINISHCANCER #immunotherapy

48-year-old colorectal cancer survivor urges people to screen early. On behalf of our entire Providence #FinishCancer Team, thank you, Leslie, for your advocacy and for sharing your story of courage and grace. KATU News Chiles Research Institute katu.com/features/famil…

Join us at the OncLive.com State of the Science Summit on April 17. Register at registration.onclive.com/state-of-the-s….

Instability in regulatory T cells may predict the efficacy of cancer #immunotherapy that combines anti-PD-1 and anti-LAG-3 antibodies, according to new work involving mice and data from patients with melanoma. Chiles Research Institute scim.ag/4cCr4iM

Rolig and Peng et al. identified mouse tumor models with high (LAG3hi) or low (LAG3lo) frequencies of LAG3+ lymphocytes. bit.ly/4lAfEjG  Annah Rolig  Chiles Research Institute

The AACR Annual Meeting is live, and we are thrilled to have members of our #FINISHCANCER team there to present their study findings! Find links to all our presentations on our blog blog.providence.org/cancer/aacr-an…. #AACR25

Excited to be in Chicago for the AACR Annual Meeting & very am much looking forward to the Keynote 689 presentation by Ravi Uppaluri, MDPhD, the discussion by Robert Ferris, MD, PhD & the dawn of a new era for patients with head & neck cancer. #AACR25 #FINISHCANCER Providence Chiles Research Institute

Dr Andy Weinberg Chiles Research Institute & AgonOx opens the #TVACT2025 at University of Hawaii Cancer Center #Honolulu - 30 yrs since 1st #TVACT1995/Shows expansion of Tu-Rx CD39+/CD103+ TIL/finds 150 unique TCR in #Melanoma pt/Diverse TCR repertoire/What are they recognizing? #cancer #immunotherapy

Great to be ⁦AHNS⁩ Annual meeting. Watch for the Immunotherapy session on Wed in which ⁦Chiles Research Institute⁩ IO Fellow Robert Herman will present updated survival from our Ph1 NIRT study. In addition, I will present data from KN689 during the evening sessions at 6pm!